company background image
UCB

UCB ENXTBR:UCB Stock Report

Last Price

€82.12

Market Cap

€15.6b

7D

-2.5%

1Y

18.3%

Updated

22 Sep, 2023

Data

Company Financials +

UCB Stock Overview

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases.

UCB fundamental analysis
Snowflake Score
Valuation2/6
Future Growth4/6
Past Performance1/6
Financial Health4/6
Dividends4/6

UCB SA Competitors

Price History & Performance

Summary of all time highs, changes and price drops for UCB
Historical stock prices
Current Share Price€82.12
52 Week High€88.80
52 Week Low€67.58
Beta0.33
1 Month Change-0.024%
3 Month Change-1.86%
1 Year Change18.26%
3 Year Change-16.02%
5 Year Change6.10%
Change since IPO1,697.25%

Recent News & Updates

Is UCB (EBR:UCB) Using Too Much Debt?

Aug 07
Is UCB (EBR:UCB) Using Too Much Debt?

Are Investors Undervaluing UCB SA (EBR:UCB) By 48%?

Jun 02
Are Investors Undervaluing UCB SA (EBR:UCB) By 48%?

Recent updates

Is UCB (EBR:UCB) Using Too Much Debt?

Aug 07
Is UCB (EBR:UCB) Using Too Much Debt?

Are Investors Undervaluing UCB SA (EBR:UCB) By 48%?

Jun 02
Are Investors Undervaluing UCB SA (EBR:UCB) By 48%?

UCB's (EBR:UCB) Upcoming Dividend Will Be Larger Than Last Year's

Apr 05
UCB's (EBR:UCB) Upcoming Dividend Will Be Larger Than Last Year's

Does UCB (EBR:UCB) Have A Healthy Balance Sheet?

Apr 03
Does UCB (EBR:UCB) Have A Healthy Balance Sheet?

Here's Why UCB (EBR:UCB) Can Manage Its Debt Responsibly

Dec 05
Here's Why UCB (EBR:UCB) Can Manage Its Debt Responsibly

These 4 Measures Indicate That UCB (EBR:UCB) Is Using Debt Reasonably Well

Sep 05
These 4 Measures Indicate That UCB (EBR:UCB) Is Using Debt Reasonably Well

Does UCB (EBR:UCB) Have A Healthy Balance Sheet?

Jun 06
Does UCB (EBR:UCB) Have A Healthy Balance Sheet?

UCB (EBR:UCB) Is Paying Out A Larger Dividend Than Last Year

Apr 23
UCB (EBR:UCB) Is Paying Out A Larger Dividend Than Last Year

UCB's (EBR:UCB) Upcoming Dividend Will Be Larger Than Last Year's

Apr 09
UCB's (EBR:UCB) Upcoming Dividend Will Be Larger Than Last Year's

UCB (EBR:UCB) Has Announced That It Will Be Increasing Its Dividend To €0.91

Mar 26
UCB (EBR:UCB) Has Announced That It Will Be Increasing Its Dividend To €0.91

Here's Why UCB (EBR:UCB) Can Manage Its Debt Responsibly

Dec 23
Here's Why UCB (EBR:UCB) Can Manage Its Debt Responsibly

Are Investors Undervaluing UCB SA (EBR:UCB) By 42%?

Dec 05
Are Investors Undervaluing UCB SA (EBR:UCB) By 42%?

Here's Why UCB (EBR:UCB) Can Manage Its Debt Responsibly

Sep 23
Here's Why UCB (EBR:UCB) Can Manage Its Debt Responsibly

UCB SA (EBR:UCB) Shares Could Be 44% Below Their Intrinsic Value Estimate

Sep 05
UCB SA (EBR:UCB) Shares Could Be 44% Below Their Intrinsic Value Estimate

UCB SA Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Jul 31
UCB SA Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Is UCB (EBR:UCB) A Risky Investment?

Jun 21
Is UCB (EBR:UCB) A Risky Investment?

UCB SA's (EBR:UCB) Intrinsic Value Is Potentially 96% Above Its Share Price

May 13
UCB SA's (EBR:UCB) Intrinsic Value Is Potentially 96% Above Its Share Price

Is UCB (EBR:UCB) Using Too Much Debt?

Mar 18
Is UCB (EBR:UCB) Using Too Much Debt?

Will Weakness in UCB SA's (EBR:UCB) Stock Prove Temporary Given Strong Fundamentals?

Feb 28
Will Weakness in UCB SA's (EBR:UCB) Stock Prove Temporary Given Strong Fundamentals?

UCB SA's (EBR:UCB) Intrinsic Value Is Potentially 54% Above Its Share Price

Feb 10
UCB SA's (EBR:UCB) Intrinsic Value Is Potentially 54% Above Its Share Price

What Makes UCB SA (EBR:UCB) A Great Dividend Stock?

Jan 20
What Makes UCB SA (EBR:UCB) A Great Dividend Stock?

Is UCB SA (EBR:UCB) Popular Amongst Institutions?

Jan 07
Is UCB SA (EBR:UCB) Popular Amongst Institutions?

UCB (EBR:UCB) Is Growing Earnings But Are They A Good Guide?

Dec 23
UCB (EBR:UCB) Is Growing Earnings But Are They A Good Guide?

With EPS Growth And More, UCB (EBR:UCB) Is Interesting

Dec 04
With EPS Growth And More, UCB (EBR:UCB) Is Interesting

UCB SA's (EBR:UCB) Share Price Not Quite Adding Up

Sep 17
UCB SA's (EBR:UCB) Share Price Not Quite Adding Up

UCB's (EBR:UCB) Earnings Are Growing But Is There More To The Story?

Aug 31
UCB's (EBR:UCB) Earnings Are Growing But Is There More To The Story?

Here's What UCB SA's (EBR:UCB) Shareholder Ownership Structure Looks Like

Aug 06
Here's What UCB SA's (EBR:UCB) Shareholder Ownership Structure Looks Like

Shareholder Returns

UCBBE PharmaceuticalsBE Market
7D-2.5%-2.0%-1.1%
1Y18.3%18.1%9.0%

Return vs Industry: UCB matched the Belgian Pharmaceuticals industry which returned 18% over the past year.

Return vs Market: UCB exceeded the Belgian Market which returned 6.8% over the past year.

Price Volatility

Is UCB's price volatile compared to industry and market?
UCB volatility
UCB Average Weekly Movement2.6%
Pharmaceuticals Industry Average Movement4.9%
Market Average Movement3.3%
10% most volatile stocks in BE Market6.8%
10% least volatile stocks in BE Market2.1%

Stable Share Price: UCB is less volatile than 75% of Belgian stocks over the past 3 months, typically moving +/- 3% a week.

Volatility Over Time: UCB's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19258,600Jean-Christophe Tellierhttps://www.ucb.com

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases. The company’s primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson’s disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; BIMZELX for treating psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa; and dapirolizumab pegol for systemic lupus erythematosus.

UCB SA Fundamentals Summary

How do UCB's earnings and revenue compare to its market cap?
UCB fundamental statistics
Market Cap€15.58b
Earnings (TTM)€332.00m
Revenue (TTM)€5.11b

46.9x

P/E Ratio

3.0x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
UCB income statement (TTM)
Revenue€5.11b
Cost of Revenue€1.63b
Gross Profit€3.48b
Other Expenses€3.15b
Earnings€332.00m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

Feb 28, 2024

Earnings per share (EPS)1.75
Gross Margin68.09%
Net Profit Margin6.50%
Debt/Equity Ratio30.3%

How did UCB perform over the long term?

See historical performance and comparison

Dividends

1.6%

Current Dividend Yield

76%

Payout Ratio